Peru study expands reptarenavirus map in boas and pythons

A newly published Animals study adds Peru to the growing map of places where reptarenaviruses are being documented in snakes, including animals of both wild and captive origin. Published October 3, 2026, the paper, “Reptarenaviruses in Wild- and Captive-Origin Boid and Pythonid Snakes in Peru,” examines viruses associated with boid inclusion body disease, a long-recognized and often devastating disease in captive boas and pythons. (mdpi.com)

That’s a notable shift in emphasis for the field. Much of the historical literature on reptarenaviruses and BIBD has come from private collections, zoos, and other managed populations. Over the past several years, though, evidence has started to point toward a broader ecological picture. A 2022 report from Costa Rica documented BIBD and reptarenavirus infection in indigenous captive and wild boa constrictors, while work from Brazil identified reptarenaviruses in native captive boas and argued that wild snakes may have helped seed viruses into captive populations. (pmc.ncbi.nlm.nih.gov)

The Peru paper's abstract frames the issue in exactly those terms: viral pathogens are an increasing threat to wildlife health and biodiversity, but free-ranging reptile virology remains under-studied. The article appears in Animals volume 16, issue 19, as article 3112, with six listed authors, including Michael Gulman, Joaquin Vasquez, and Robert J. Ossiboff in addition to the three authors provided in the source summary. Based on the journal listing, the paper is a 13-page open-access article, suggesting a primary research report rather than a commentary or review. (mdpi.com)

The clinical backdrop is important for veterinary readers. Merck Veterinary Manual describes inclusion body disease of boid snakes as a reptarenavirus-associated condition that can produce chronic disease, neurologic signs, and death. Experimental and observational studies have also shown species differences: pythons may develop more rapid or severe clinical disease, while boas can remain infected for longer periods with fewer obvious signs, making them plausible silent carriers in some settings. That carrier state is one reason diagnostic screening has become such a priority for collections and intake facilities. (merckvetmanual.com)

Diagnostic complexity is another reason this Peru report matters. Reptarenaviruses are genetically diverse, and co-infections are common in affected snakes. A 2023 multiplex RT-PCR paper noted that inclusion bodies remain the diagnostic gold standard for BIBD, but clinically healthy carriers may lack detectable inclusions, meaning molecular assays are essential for surveillance and control. That same paper emphasized that assay design has to account for viral diversity, a point especially relevant when viruses are being characterized in understudied geographies like Peru. (mdpi.com)

Direct outside commentary on the new Peru paper was limited at the time of writing, but the broader field has been consistent on the biosecurity message. Veterinary Partner, a VIN client education resource, stresses quarantine and testing of incoming snakes, including PCR-based screening, because infected animals may introduce reptarenaviruses into established collections. That advice takes on added weight when surveillance studies identify virus signal in animals with wild origin, confiscation history, or uncertain movement pathways. The international wildlife-trade backdrop also matters here: CITES describes its trade database as the official record of reported international wildlife trade, and snake trade has long been a concern in conservation and health discussions because animal movement can facilitate pathogen spread alongside welfare and biodiversity risks. (veterinarypartner.vin.com)

Why it matters: For veterinary professionals, especially those in exotic animal practice, diagnostic labs, zoos, sanctuaries, and wildlife rescue, this study reinforces that reptarenavirus risk assessment should include both collection management and source history. A snake's wild origin shouldn't be treated as reassuring by default, and a clinically normal animal may still warrant testing before introduction into a collection. The findings also support a One Health-style wildlife health view: pathogen discovery in free-ranging or recently wild-caught reptiles can change how clinicians think about quarantine, movement controls, and the epidemiologic origins of disease previously framed as mainly a captive-population problem. (pmc.ncbi.nlm.nih.gov)

What to watch: The next steps are likely to be full genomic characterization of the Peru viruses, better estimates of prevalence by species and origin, and closer attention to whether any of the detected strains align with viruses already seen in captive collections elsewhere. If that link emerges, the paper could become an important reference point in discussions about trade, rescue intake, and surveillance protocols for boid and pythonid snakes moving between wild, confiscated, and managed settings. (mdpi.com)